Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review

Neurology and Therapy

Volumn 3, Issue 1, 2014, Pages 29-39

  Kolb Sobieraj, Channa ^a,b   Gupta, Sahil ^a,b   Weinstock Guttman, Bianca ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b JACOBS NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Clinical trials; Disease modifying therapies; Laquinimod; Multiple sclerosis; Neurology; Neuroprotection

Indexed keywords

ALEMTUZUMAB; BLOOD CLOTTING FACTOR 5 LEIDEN; BRAIN DERIVED NEUROTROPHIC FACTOR; GADOLINIUM; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 4; LAQUINIMOD; NATALIZUMAB; PLACEBO; ROQUINIMEX; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTHRALGIA; BACKACHE; BUDD CHIARI SYNDROME; CENTRAL NERVOUS SYSTEM; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; EXPANDED DISABILITY STATUS SCALE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HEADACHE; HEART INFARCTION; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; INFLAMMATORY INFILTRATE; LIVER FUNCTION TEST; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NERVE CELL DIFFERENTIATION; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERICARDITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURISY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; TREATMENT OUTCOME;

EID: 84977139159     PISSN: 21938253     EISSN: 21936536     Source Type: Journal    
DOI: 10.1007/s40120-014-0017-6     Document Type: Review

References (37)

1. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366:1000–9.
2. Noseworthy JH, Wolinsky JS, Lublin FD, et al. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology. 2000;54:1726–33.
3. Wolinsky JS, Narayana PA, Noseworthy JH, et al. Linomide in relapsing and secondary progressive Ms: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology. 2000;54:1734–41.
4. Tan IL, Lycklama a Nijeholt GJ, Polman CH, Ader HJ, Barkhof F. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Mult Scler. 2000;6:99–104.
5. Jonsson S, Andersson G, Fex T, et al. Synthesis and biological evaluation of new 1,2-Dihydro-4-Hydroxy-2-Oxo-3-Quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem. 2004;47:2075–88.
6. Brunmark C, Runstrom A, Ohlsson L, et al. The new orally active immuno regulator laquinimod (Abr-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2002;130:163–72.
7. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell. 1996;85:299–302.
8. Prat A, Antel J. Pathogenesis of multiple sclerosis. Curr Opin Neurol. 2005;18:225–30.
9. Brück W, Wegner C. Insight into the mechanism of laquinimod action. J Neurol Sci. 2011;306:173–9.
10. Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (Abr-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 Cytokine Tgf-Beta in Lewis Rats. J Neuroimmunol. 2004;156:3–9.
11. Wegner C, Stadelmann C, Pförtner R, et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010;227:133–43.
12. Gurevich M, Gritzman T, Orbach R, Tuller T, Feldman A, Achiron A. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study. J Neuroimmunol. 2010;221:87–94.
13. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677–736.
14. Thöne J, Ellrichmann G, Seubert S, et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol. 2012;180:267–74.
15. Suhs K-W. Effects of laquinimod on axon degeneration in autoimmune optic neuritis. Mult Scler 2007;13:S7–S273.
16. Thone J, Gold R. Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Drug Metab Toxicol. 2011;7:365–70.
17. Polman C, Barkhof F, Sandberg-Wollheim M, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology. 2005;64:987–91.
18. Comi G, Abramsky O, Arbizu T, et al. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler. 2010;16:1360–6.
19. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;371:2085–92.
20. Vollmer T, Soelberg Sorensen P, Arnold DL, on behalf of the BRAVO study group. A placebo-controlled and active comparator phase III trial (Bravo) for relapsing-remitting multiple sclerosis. Amsterdam, Netherlands: 5th joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis; 2011.
21. Clinicaltrials.gov. The efficacy and safety and tolerability of laquinimod in subjects with relapsing remitting multiple sclerosis (RRMS) (CONCERTO). http://clinicaltrials.gov/show/NCT01707992 (last accessed April 9, 2014).
22. Waubant E. Overview of treatment options in multiple sclerosis. J Clin Psychiatry. 2012;73:e22.
23. La Mantia L, Munari LM, Lovati R. Glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev. 2010;CD004678.
24. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The multiple sclerosis collaborative research group (MSCRG)’. Ann Neurol. 1996;39:285–94.
25. IFNB Multiple Sclerosis Study Group. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis I. Clinical results of a multicenter, randomized, double‐blind, placebo-controlled trial. Neurology. 1993;43:655.
26. Thone J, Ellrichmann G. Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits. Drug Healthc Patient Saf. 2013;5:37–47.
27. Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol. 2011;10:1026–34.
28. Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401.
29. Cohen JA, Barkhof F, Comi G, et al. Fingolimod versus intramuscular interferon in patient subgroups from transforms. J Neurol. 2013;260:2023–32.
30. Doggrell SA. Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387–401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402–15. Expert Opin Pharmacother. 2010;11(10):1777–81.
31. O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293–303.
32. Kappos L, Comi G, Confavreux C. The efficacy and safety of teriflunomide in patients with relapsing MS: results from tower, a phase III, placebo-controlled study. Lyon, France: 28th Congress of the European committee for research and treatment in multiple sclerosis (ECTRIMS); 2012.
33. Clinicaltrials.gov. A study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis (TENERE). http://clinicaltrials.gov/show/NCT00883337 (last accessed April 9, 2014).
34. Bar-Or A, Gold R, Kappos L, et al. Clinical efficacy of BG-12 (Dimethyl Fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the define study. J Neurol. 2013;260:2297–305.
35. Hutchinson M, Fox RJ, Miller DH, et al. Clinical efficacy of BG-12 (Dimethyl Fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the confirm study. J Neurol. 2013;260:2286–96.
36. Barkhof F, Calabresi P, Miller D, Reingold S. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009;5(256–266):39.
37. Rammohan K, Shoemaker J. Emerging multiple sclerosis oral therapies. Neurology. 2010;74:s47–53.